

22 September 2016

**Oncimmune Holdings plc  
("Oncimmune" or the "Company")**

**Maarten Brusse appointed Chief Commercial Officer Asia**

Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*<sup>®</sup> platform technology, announces that it has appointed Maarten Brusse, as Chief Commercial Officer Asia.

Maarten is a seasoned international business executive in laboratory diagnostics with proven success record in EMEA and APAC regions. He has a proven track record in the sales of medical devices and has worked in different fields including science, laboratory, manufacturing, field service, sales, marketing and general management. As Chief Commercial Officer Asia he will be leading the sales process in the region as well as targeting out-license opportunities.

He has over two decades of relevant experience in medical devices with particular expertise in the Asia region. Most recently Maarten was Senior Director Molecular Sales EMEIA at Luminex Corporation since 2013 and prior to that he was General Manager and Commercial Director at Abbot Molecular from 2009. He also worked as Sales Manager NEMEA at AcroMetrix Europe BV between 2007-2209.

**Geoffrey Hamilton-Fairley, CEO of Oncimmune commented:** "As stated at the time of IPO, we were planning to target the Asia markets and we are delighted to have attracted someone of Maarten's calibre to lead Oncimmune's growth in this region. His very relevant experience and specific knowledge of working in the Asian markets will be invaluable to us as we target sales and out-licensing opportunities for the *EarlyCDT*<sup>®</sup> platform technology."

**Commenting on his appointment, Maarten Brusse said:** "After meeting the Company and understanding the potential of the *EarlyCDT*<sup>®</sup> platform technology, I was convinced that this can transform cancer detection and save many lives. I am very pleased to accept the position of CCO Asia look forward to being part of the future success of the Company."

**About Oncimmune**

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary *EarlyCDT*<sup>®</sup> platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, *EarlyCDT*<sup>®</sup>-Lung, was launched in 2012, as a CLIA test in the USA and since then over 145,000 commercial tests have been sold. *EarlyCDT*<sup>®</sup>-Lung is available through physicians in the US and also privately in the UK and other regions. *EarlyCDT*<sup>®</sup>-Lung is being used in the largest



ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,000 high-risk smokers. *EarlyCDT*<sup>®</sup> tests for liver and ovarian cancer are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information visit [www.oncimmune.com](http://www.oncimmune.com)

**For further information:**

**Oncimmune Holdings plc**  
**Geoffrey Hamilton-Fairley, Chief Executive Officer**  
[contact@oncimmune.co.uk](mailto:contact@oncimmune.co.uk)

**Media enquiries:**

**Consilium Strategic Communications**  
Chris Gardner, Mary-Jane Elliott, Matthew Neal, Lindsey Neville  
[oncimmune@consilium-comms.com](mailto:oncimmune@consilium-comms.com)  
+44 (0) 20 3709 5708